Stock screener

ICCC

Conviction 90HealthcareScan · Mon, Aug 10, 2026
ICCC$11.02+0.18%
ResistanceSupportVol 14Insider buy
63 bars
Vol MA14 20.23K
May 11May 28Jun 16Jul 6Jul 23Aug 10
IMMUCELL CORP /DE/IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESwww.immucell.com ↗
Price11.02
Change+0.18%
Gap-0.64%
Rel volume1.52×
Avg volume24.46K
Avg $ vol271.79K
SMA 2011.08
SMA 5010.44
SMA 2007.63
Price vs 50+5.55%
Price vs 200+44.46%
MA stackbullish
50/200 cross—
Supertrendup · 9.83
RSI (14)53
MACD hist-0.07
MACD cross—
Stoch %K / %D44 / 44
ADX (14)27
+DI / −DI16 / 15
RSI divergenceBearish
MACD divergenceBearish
ATR %+4.15%
ADR %4.31%
52w high11.72
52w low4.56
From 52w high-5.97%
Above 52w low+141.67%
New 52w highNo
SqueezeOn · 6d
Bollinger width7.02%
%B0.42
Donchian pos32.50%
Donchian high12.10
Donchian low10.50
AVWAP (52w high)11.14
vs AVWAP high-1.05%
AVWAP (52w low)8.15
vs AVWAP low+35.17%
OBV trendUp
Chaikin MF (20)-0.04
Today vs 20d1.52×
Avg vol (14d)20.23K
Avg vol (20d)24.46K
Avg $ vol (20d)271.79K
Market cap99.7M
RS 3m (vs SPY)+24.17%
RS 6m (vs SPY)+65.98%
RS line new highNo
Trend template8/8
Technical rank79.1
1 week-0.18%
1 month+1.19%
3 months+36.89%
6 months+76.60%
1 year+79.48%
YTD+86.15%
P/E-95.86
P/B3.42
P/S3.61
P/FCF81.39
EPS-0.1200
Div yield—
ROE-3.57%
ROA-2.36%
Debt/Eq0.30
Current4.82
EV/EBITDA22.91
Gross margin41.40%
Net margin-3.76%
Rev growth4.34%
EPS growth51.78%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value101.59M
Revenue10.36M
Net income1.94M
Gross profit4.66M
Free cash flow1.22M
IndustryIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
ExchangeNasdaq
Shares out9.05M
Employees73
ListedWed, Jul 8, 1987
Free float6M
Float %66.3%
Short interest14.05K
Days to cover0.3d
Short volume42.1%
Squeeze score11 / 100
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeA+
Conviction90 / 100
Pattern quality—
Tech rank79.1 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance11.89
Support9.38
Days since event—
Candle confirm—
News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ICCC

All disclosures →
No recent disclosed trades by Congress in ICCC. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ICCC · 10 buys

InsiderSideShares
te Boekhorst Paul Francis Olivier
President and CEO · Common Stock, par value $.01 per share · 2026-06-18
Buy8K
Turner Kathy V
Director · Non Qualified Stock Options (Right to buy) · 2026-04-15
Grant17.9K
Tomsche David Scott
Director · Non Qualified Stock Options (Right to buy) · 2026-04-15
Grant11.93K
Basse Gloria F
Director · Non Qualified Stock Options (Right to buy) · 2026-04-15
Grant11.93K
Wainman Paul R
Director · Non Qualified Stock Options (Right to buy) · 2026-04-15
Grant11.93K
Wainman Paul R
Director · Non Qualified Stock Options (Right to buy) · 2025-04-16
Grant10K
Rosgen Steven T.
Director · Non Qualified Stock Options (Right to buy) · 2025-04-16
Grant10K
Basse Gloria F
Director · Non Qualified Stock Options (Right to buy) · 2025-04-16
Grant10K
Tomsche David Scott
Director · Non Qualified Stock Options (Right to buy) · 2025-04-16
Grant10K
Brockmann Bobbi Jo
VP of Sales and Marketing · Incentive Stock Options (Right to buy) · 2025-04-16
Grant5K

SEC filings

EDGAR filings in ICCC · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.